Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region
- PMID: 22614711
- DOI: 10.1097/PAT.0b013e3283532565
Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region
Abstract
Aim: Approximately 40-60% of melanomas from Caucasian populations carry activating mutations in the BRAF oncogene, with the most common being the p.Val600Glu (V600E) hotspot mutation in exon 15. The aim of the present study was to investigate the frequency of the less common p.Val600Lys (V600K) mutation in metastatic melanoma from a high incidence region.
Method: Dideoxy sequencing and fluorescent single strand conformation analysis were used to screen for mutations in exon 15 of BRAF in 183 cases of metastatic melanoma.
Results: The overall incidence of BRAF mutation (89/183, 49%) was very similar to other large studies of Caucasian populations. However, the frequency of the p.Val600Lys mutation was higher than in most other studies and comprised almost one-third of all BRAF mutations in our cohort (27/89, 30%).
Conclusion: BRAF p.Val600Lys mutations were present at a relatively high frequency in this cohort of metastatic melanoma patients (27/183, 15%). Assays used to screen for BRAF mutations in the clinic should be robust enough to detect the p.Val600Lys mutation, as this may have therapeutic implications.
Similar articles
-
Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.Hum Pathol. 2005 May;36(5):486-93. doi: 10.1016/j.humpath.2005.03.015. Hum Pathol. 2005. PMID: 15948115
-
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.J Clin Oncol. 2011 Apr 1;29(10):1239-46. doi: 10.1200/JCO.2010.32.4327. Epub 2011 Feb 22. J Clin Oncol. 2011. PMID: 21343559
-
Lymph node metastases of melanoma: challenges for BRAF mutation detection.Hum Pathol. 2015 Jan;46(1):113-9. doi: 10.1016/j.humpath.2014.09.014. Epub 2014 Oct 7. Hum Pathol. 2015. PMID: 25456393
-
BRAF kinase in melanoma development and progression.Expert Rev Mol Med. 2008 Feb 18;10:e6. doi: 10.1017/S1462399408000604. Expert Rev Mol Med. 2008. PMID: 18279546 Review.
-
[BRAF mutation testing for the choice of melanoma treatment].Arkh Patol. 2012 Sep-Oct;74(5):65-71. Arkh Patol. 2012. PMID: 23342664 Review. Russian.
Cited by
-
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.Lancet Oncol. 2014 Mar;15(3):323-32. doi: 10.1016/S1470-2045(14)70012-9. Epub 2014 Feb 7. Lancet Oncol. 2014. PMID: 24508103 Free PMC article. Clinical Trial.
-
Comparative evaluation of the new FDA approved THxID™-BRAF test with High Resolution Melting and Sanger sequencing.BMC Cancer. 2014 Jul 19;14:519. doi: 10.1186/1471-2407-14-519. BMC Cancer. 2014. PMID: 25037456 Free PMC article.
-
Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database.Exp Biol Med (Maywood). 2021 Jan;246(1):31-39. doi: 10.1177/1535370220959657. Epub 2020 Oct 5. Exp Biol Med (Maywood). 2021. PMID: 33019809 Free PMC article.
-
A New Bioassay Platform Design for the Discovery of Small Molecules with Anticancer Immunotherapeutic Activity.Mar Drugs. 2020 Nov 29;18(12):604. doi: 10.3390/md18120604. Mar Drugs. 2020. PMID: 33260400 Free PMC article.
-
Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.Br J Cancer. 2014 Jul 15;111(2):292-9. doi: 10.1038/bjc.2014.287. Epub 2014 Jun 10. Br J Cancer. 2014. PMID: 24918823 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials